Head of real estate for billionaire Tom Steyer says it's a major factor.
Veteran investor has sold 14 times, pressuring bank's share price.
When Social Security started, the life expectancy for someone collecting was six to eight years, but now we're pushing past 20 years, says advisor.
The 25-year veteran of the industry brings his experience from Raymond James, Invesco and Barclays to the Las Vegas, Nevada-based firm.
Getting down with Josh Brown – CEO and blog superstar talks about new book and the state of the RIA business.
“The numbers are wrong," says broker, who made $1.5 million after guiding clients to invest in friend’s firm, according to the Bureau of Securities.
Advisor talks about incorporating financial therapy into her wealth management offering.
CEO says S&P 500's rate of growth, led by the top 10 names, is unsustainable.
If there is not a cultural fit between the firm and the advisor, then nothing else matters, insists CEO.
The financial industry veteran, supported by a team of wealth advisors, will drive the firm's private banking expansion in Pennsylvania
Advisor fees have remained relatively steady despite free compression across the industry. However, clients now expect more bang for their buck, says AssetMark's Matthew Matrisian.
The good, the bad, and the ugly: How CEO connects the numbers to a client's life story.
Dig deeper into latest technology trends with our expert speakers at the upcoming RIA Activate event.
Latest research reveals seven in 10 women have investments the US equity market, but financial stress still keeps a strong majority up at night.
New Deloitte outlook offers insights on active ETFs, alternatives' mixed performance, and advisors' role in the rise of private credit.
The East Coast deal marks the eighth transaction this year for the Ohio-based independent, adding to its $23.6B in client assets.
Could the US economy not only avoid slowdown but reignite inflationary influences?
High costs of borrowing for homes, cautious lenders for CRE barriers to investing.
Third quarter results may not live up to expectations.
Will activist investor help solve drugmaker's post-pandemic challenges?
